Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb-IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation)-Reference-Cited by-同舟云学术

Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb-IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation)

Published:2015-03 Issue:6 Volume:115 Page:711-715
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

De Luca Giuseppe,van't Hof Arnoud W.J.,Gibson C. Michael,Cutlip Donald,Zeymer Uwe,Noc Marko,Maioli Mauro,Zorman Simona,Gabriel H. Mesquita,Emre Ayse,Rakowski Tomasz,Gyongyosi Maryann,Huber Kurt,Bellandi Francesco,Dudek Dariusz

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction;De Luca;Am J Emerg Med,2009

2. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status;De Luca;Prog Cardiovasc Dis,2008

3. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction;De Luca;Thromb Haemost,2005

4. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials;De Luca;Am Heart J,2007

5. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials;De Luca;Thromb Haemost,2009

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Future Roles of Glycoprotein IIb–IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction;Biomedicines;2024-09-04

2. Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation;Journal of Thrombosis and Thrombolysis;2023-08-10

3. Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study;American Heart Journal;2023-08

4. Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐ elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial;American Heart Journal;2023-04

5. Diabetes Mellitus Is Still a Strong Predictor of Periprocedural Outcomes of Primary Percutaneous Coronary Interventions in Patients Presenting with ST-Segment Elevation Myocardial Infarction (from the ORPKI Polish National Registry);Journal of Clinical Medicine;2022-10-25